Login / Signup

The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.

Angelo CastelloLuca ToschiSabrina RossiEmanuela MazziottiEgesta Lopci
Published in: Journal of cancer research and clinical oncology (2020)
IMPI at the first restaging, combining both inflammatory and metabolic biomarkers, was correlated with PFS and OS. IMPI can be a potentially valuable tool for identifying NSCLC patients who are likely to benefit from ICI.
Keyphrases
  • end stage renal disease
  • small cell lung cancer
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • oxidative stress
  • cell therapy
  • cell cycle
  • patient reported outcomes
  • tyrosine kinase